Combined HP (13)C Pyruvate and (13)C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts

A vast majority of BRAF V600E mutated melanoma patients will develop resistance to combined BRAF/MEK inhibition after initial clinical response. Resistance to targeted therapy is described to be accompanied by specific metabolic changes in melanoma. The aim of this work was to evaluate metabolic ima...

Descripción completa

Detalles Bibliográficos
Autores principales: Farah, Chantale, Neveu, Marie-Aline, Yelek, Caner, Bouzin, Caroline, Gallez, Bernard, Baurain, Jean-François, Mignion, Lionel, Jordan, Bénédicte F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945537/
https://www.ncbi.nlm.nih.gov/pubmed/35327519
http://dx.doi.org/10.3390/biomedicines10030717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945537/
https://www.ncbi.nlm.nih.gov/pubmed/35327519
http://dx.doi.org/10.3390/biomedicines10030717

Ejemplares similares